BC Partners announced the sale of a majority share in Pharmathen to the international private equity company Partners Group. The value of the transaction is € 1.6 bln.
Athens, Greece: 19 July 2020
Founded in 1969 in Athens, Pharmathen develops and produces generic drugs. The company specialises in the development of “extended release” technologies, with innovative research and development capabilities.
In 2015, Pharmathen was acquired by BC Partners in 2015 for € 475 mln.
Since then, Pharmathen has grown into a technology–driven company leading a highly attractive industry, with EBITDA growth of 16% on a weighted annual average over the last 5 years.
Nikos Stathopoulos, Partner and Head of BC Partners said:
“At Pharmathen, we saw an opportunity to make a significant investment in a high quality business to accelerate its organic growth and develop the company into a global leader. During the period of our ownership, we invested more than € 250 mln in Research and Development and in the new FDA certified production facilities. We almost doubled the number of employees and implemented projects that really transformed the company. This has allowed us to reposition Pharmathen as a technology – driven company in a very attractive industry. We have built a truly admirable company, which I am convinced, will continue to stand out under the management of Partners Group.”
Dimitris Kadis, CEO of Pharmathen added:
“I want to thank the BC team for their cooperation over the last six years. Their investment, support and guidance have enabled them to be a key player in taking the company to the next level as a global leader in drug development and delivery. “
Navigator Consulting provides investment advisory, due diligence and risk analysis for investments in Greece, Cyprus and internationally.
Money Review. 19 July 2021
NavInvest Greece. 2 July 2021
NavInvest Greece. 30 June 2021
NavInvest Greece. 13 June 2021
Navigator Consulting. 27 August 2020
Navigator Consulting. May 19, 2020
NavInvest Greece. 4 May 2020